Evaluating residual anti-Xa levels following discontinuation of treatment-dose enoxaparin in patients presenting for elective surgery: an infographic

Reg Anesth Pain Med. 2024 Feb 5;49(2):102-103. doi: 10.1136/rapm-2023-104873.

Authors

Daryl S Henshaw^{1

2}, Eric S Schwenk³, Rajnish K Gupta⁴

Affiliations

¹ Anesthesiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
² Atrium Wake Forest Baptist Health, Medical Center Boulevard, Winston-Salem, North Carolina, USA.
³ Anesthesiology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
⁴ Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA raj.gupta@vumc.org.

PMID: 37591616
DOI: 10.1136/rapm-2023-104873

No abstract available

Keywords: anticoagulants; drug-related side effects and adverse reactions; pharmacology; regional anesthesia.

MeSH terms

Anticoagulants / adverse effects
Data Visualization
Enoxaparin* / adverse effects
Factor Xa Inhibitors / adverse effects
Humans
Venous Thromboembolism*

Substances

Enoxaparin
Anticoagulants
Factor Xa Inhibitors